AbCellera Investor Conference Presentation Deck

JPM HEALTHCARE CONFERENCE 2024 COPYRIGHT ABCELLERA 11 OUR ENGINE: T-CELL ENGAGER PLATFORM Reducing dose-limiting toxicity associated with cytokine release. Selection of CD3 binders that achieve potent cell killing with very low cytokine release on an undisclosed target. Example molecule Potent tumor-cell killing % Tumor-cell killing 100- 80- 9 40- 20- • 10 - 0 10-6 10-510-4 10-3 10-2 10-1 100 101 10² Concentration (nM) Low cytokine release TNFa (pg/mL) 600- 500- 400- 300- 200- 100- e . ● • 106 105 10-4 10-3 10-2 101 100 10¹ 10² Concentration (nM) AbCellera molecule Clinical benchmark 1 Clinical benchmark 2

View entire presentation